After FDA holdups, the Novavax COVID-19 vaccine has secured full FDA approval.

It’s been a unique journey to approval, with prospects for the vaccine thrown into doubt in April when the approval target came and went.

Reports suggest political interference at the FDA may have delayed the decision.

An arthritis drug has been shown to prevent brain-damaging seizures in mouse models of epilepsy, restoring memory 🧠

If the drug proves viable in humans, it could represent a first-of-its-kind therapeutic for providing permanent seizure suppression.

@uwmadison.bsky.social

A weight loss drug that expands in the stomach to create a sustained feeling of fullness has shown promising three-month Phase 2 clinical trial results.

The treatment, known as Sirona, is taken as a pill and is positioned to help patients transition off of GLP-1 medications.

After two years the FDA has lifted the clinical hold on Entrada Therapeutics Duchenne muscular dystrophy (DMD) drug.

The therapy, which is set to enter a phase 1b study in the US in 2026, is being evaluated for its potential to “skip” over the faulty section of the RNA transcript for dystrophin.

Repurposing amlodipine, a common blood pressure drug, could provide a safer alternative to existing ADHD medicines 💊

Existing treatments can be associated with significant side effects. New research from the University of Surrey highlights the potential of amlodipine as a novel treatment.

New findings from University of North Carolina researchers show that a diabetic infection environment can drive the evolution of antibiotic resistance, contributing to the global AMR crisis. 🦠

Check out my full coverage of this research below.

Last week the US FDA approved Journavx, the first new class of pain management medicine to be approved in the US since 1998 💊

The approval is a huge step forward in the battle against opioid addiction.

Further breakthroughs may be on the way in the form of a nanoparticle-delivered therapeutic.

Five years since the pandemic, long COVID remains an unsolved puzzle with no consensus on how to treat or prevent the condition 😷

However, researchers have begun to make strides in understanding the condition and in particular its impact on the brain.

New findings from the NIH RECOVER Initiative suggest that COVID-19 infection may be associated with an increased risk of chronic fatigue 🛌

These findings add to growing evidence that infections, including those caused by SARS-CoV-2, can lead to ME/CFS.

CRISPR screening of lab-grown “mini-guts” could lead to new treatments for inflammatory bowel disease 🧫

Identifying the underlying cause of IBD has been challenging, in part due to the difficulty in modeling the disease. However, a new organoid biobank could help us better understand the disease.

Recent headlines have been flooded with warnings of a possible pandemic threat following a surge in hMPV cases in China 🦠

But ✨thankfully ✨ experts seem to agree that the situation shouldn’t trigger fears of a larger pandemic threat given the nature of the virus.